F-PSMA-1007 is a radiotracer for prostate cancer staging that lacks large validation studies for its diagnostic accuracy compared to traditional methods like histopathology.
A trial evaluated 99 men with intermediate to high-risk prostate cancer, measuring the sensitivity and specificity of F-PSMA-1007 PET/CT against lymph node dissection results.
The results indicated high specificity (89.9%) but moderate sensitivity (53.3%), suggesting that while it’s effective for certain detections, it shouldn’t replace extensive surgical procedures for accurate staging.